Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Manufacture Business Practice, Vaccines, COVID-19

Is it Time to Reevaluate Our Priorities?

“The whole research and development community is working hard to bring us that [COVID-19] breakthrough sooner rather than later,” wrote Stephanie Sutton in her November editorial (1). And here we are, just one month later, with not one but three breakthroughs.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

  1. Stephanie Sutton, “Beyond the Storm,” The Medicine Maker (2020). Available at: https://bit.ly/2VkGAJq
  2. Pfizer, “Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints” (2020). Available at: https://bit.ly/3mnKX1X
  3. Moderna, “Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study” (2020). Available at: https://bit.ly/33uKX9a 
  4. AstraZeneca, “AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19” (2020). Available at: https://bit.ly/36naZgA 
  5. BMJ, “Peter Doshi: Pfizer and Moderna’s “95% effective” vaccines—let’s be cautious and first see the full data” (2020). Available at: https://bit.ly/37gemVG 
  6. Stat News, “‘A huge experiment’: How the world made so much progress on a Covid-19 vaccine so fast” (2020). Available at: https://bit.ly/39tpy3S 

About the Author

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register